Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gleevec Maintenance in Extensive-Stage SCLC
NCT00156286Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Mar 2002
- Primary completion
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in small cell lung cancer (SCLC), sponsored by University of Michigan Rogel Cancer Center. Started Mar 2002; status: completed.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00156286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00156286.